|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for CYP19A1(NM_000103.3) Search again
Product ID:
HQP003904
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX, P-450AROM
Gene Description:
cytochrome P450 family 19 subfamily A member 1
Target Gene Accession:
NM_000103.3(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Summary
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids.
Gene References into function
- Role of aromatase in endometrial disease.
- Modulation of aromatase expression in human breast tissue.
- Aromatase and COX-2 expression in human breast cancers.
- Regulation of aromatase activity in bone-derived cells: possible role of mitogen-activated protein kinase.
- Aromatase in atherosclerotic lesions of human aorta.
- Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents.
- Analysis of transcriptional regulation of human breast aromatase by in vitro and in vivo studies.
- The potential role of estrogen in aromatase regulation in the breast.
- Peptide inhibition of cytokine-stimulated aromatase activity in breast tissue fibroblasts.
- Identification of the regulatory regions of the human aromatase P450 (CYP19) gene involved in placenta-specific expression.
- Regulation of aromatase by nuclear receptors.
- Tissue-specific expression of the human CYP19 (aromatase) gene in ovary and adipose tissue of transgenic mice.
- 17alpha-methyl testosterone is a competitive inhibitor of aromatase activity in Jar choriocarcinoma cells and macrophage-like THP-1 cells in culture.
- Phosphorylation processes mediate rapid changes of brain aromatase activity.
- A comparative approach to structure-function studies of mammalian aromatases.
- the effects of several paracrine and/or autocrine signaling pathways in the regulation of expression of aromatase in breast cancer cells identifies complex relationships
- role in blood pressure
- Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis
- Association of the CYP19 gene polymorphism with risk of endometriosis in Japanese women. not significantly different between the groups. An increased frequency of the D/D genotype. 3 bp I/D polymorphism may be weakly associated with susceptibility.
- regulation of expression in preadipocytes by liver receptor homologue-1
- aromatase expression is low in TIL but may have some functional significance for the estrogen-dependent growth of breast cancer tissue
- both transactivation and down-regulation of estrogen receptor alpha by adrenal androgens increase with aromatase overexpression in transfected MCF7 cells
- review: gene expression regulation of P450arom in Leydig cells and in germ cells and role in spermatogenesis
- Spatially heterogeneous expression of aromatase P450 through promoter II is closely correlated with the level of steroidogenic factor-1 transcript in endometrioma tissues.
- WT1 and DAX-1 inhibit its expression in human endometrial and endometriotic stromal cells
- Promoter I.7 is a GATA-2-regulated endothelial promoter of the human CYP19 gene and may increase estrogen biosynthesis in vascular endothelial cells of breast cancer.
- Aromatase (P450arom) catalyzes conversion of testosterone to estradiol, androstenedione to estrone, and 16a-hydroxylated dehydroepiandrosterone to estriol. Encoded by human CYP19 gene spanning about 123 kb with a coding region of 9 exons. Review.
- releasing of aromatase of lung cancer tissue, which catalyzes androgen to change into estrogen, into external blood might be the major reason of the increase of estradiol and the decrease of testosterone in external blood.
- Review. The P450arom plays a role in development, reproduction, sexual differentiation and behaviour, but also in bone and lipid metabolisms, brain functions and diseases such as breast and testicular tumors.
- Review. Aromatase deficiency and its implications for reproduction and sex behavior are discussed.
- C to A substitution in intron V, at position -3 of the splicing acceptor site before exon VI of the CYP19 gene causes of loss of aromatase. The mRNA leads to a frameshift and a premature stop codon 8 nucleotides downstream the end of exon V.
- Human aromatase activity is critical for maintenance of early and mid pregnancy, in regulating parturition in late pregnancy, and for development of fetal gonadocytes and sexual differentiation of brain, especially the hypothalamic-gonadal axis.
- cytochrome P450(aromatase) mRNA was not detected in the ovaries studied
- Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts
- Data demonstrate the expression of aromatase mRNA and protein in human purified spermatozoa, and suggest that aromatase could be involved in the acquisition of sperm motility.
- aromatase activity was up-regulated by activin stimulation through ActRIB in KGN cells.
- results indicate that, in premenopausal women, a short microsatellite in the fourth intron of the CYP19 gene is associated with elevated androgens, perturbed regulation of the hypothalamic-pituitary-adrenal axis, and abdominal obesity
- P-450AROM expression has been demonstrated in ejaculated immature sperm cells.
- Vitamin D, testosterone, estrogens and glucocorticoids regulate CYP19 gene expression in human primary osteoblasts. Main promoter appears to be promoter I.4.
- activating transcription factor 1(AP-1) motif is important in determining the up-regulatory effects induced by leptin on aromatase expression in MCF-7 breast cancer cells
- Heterozygous inversions in chromosome 15q21.2-3 in the aromatase gene resulted in severe estrogen excess owing to the overexpression of aromatase in many tissues.
- CYP19 gene polymorphisms may jointly influence bone mass and the rate of bone loss in older African-American women
- Regulation of aromatase by PGE(2) is complex and may influence the development and progression of hormone-dependent breast cancer.
- Estradiol upregulates aromatase expression by a nongenomic action of estrogen receptor alpha via cross-talk with growth factor-mediated pathways.
- the aromatase enzyme may exert a direct modulatory action on bone metabolism at the tissue level in elderly men.
- Androgens up-regulate aromatase gene expression in purified adult rat germ cells whereas estrogens exert an opposite effect.
- These findings suggest that increased protein levels and DNA binding of USF1 and USF2 mediate the inhibitory effects of hypoxia and of Mash-2 on CYP19 gene expression in human placenta
- Genetic polymorphism of CYP19 are associated with familial prostate carcinoma risk.
- Polymorphisms in the CYP19 gene are associated with bone gain in response to hormone replacement therapy.
- Regulation of cytochrome P450 gene expression in gonadial cells.
- Modulation of SHP expression and/or activity in adipose tissue may therefore have significant effects on aromatase expression and estrogen production in breast adipose tissue.
- Most low-grade endometrial stromal sarcomas express aromatase.
- both cytochrome P450, family 17 and cytochrome P450, family 19 are candidate genes for osteoporosis in postmenopausal women
- results indicate that endometrial aromatase mRNA levels can identify women at increased risk of fertilization in vitro treatment failure
- aromatase has a role in estrogen synthesis in the breast and in breast cancer [review]
- Gene for this subunit of the aromatase enzyme complex is not likely to be a major factor in the development of individual differences in male sexual orientation.
- mutations in CYP19 is associated with Aromatase deficiency
- CYP19 genetic polymorphism is associated with endometrial cancer
- Gene spans region consisting of 30 kb coding region and 93 kb regulatory region (approximately 123 kb total length). Its regulatory region contains at least 10 distinct promoters regulated in tissue- or signaling pathway-specific manner. (Review)
- Catalyzes formation of estrogen under control of alternatively used promoters. Each promoter regulated by tissue- and hormone-specific signaling pathway. Regulatory mechanisms in ovary, adipose tissue, placenta, bone, brain, and neoplasms.
- Key enzyme for biosynthesis of estrogen, which is an essential hormone for the establishment and growth of endometriosis. Aromatase inhibitors could decrease pelvic pain associated with endometriosis. (Review)
- Leiomyoma cells convert circulating androstenedione into estrone (via aromatase), then into active form of estrogen, estradiol (via 17beta-HSD type I). Potential uses of aromatase inhibitors. (Review)
- This study demonstrates local estrogen biosynthesis in prostate-induced aromatase gene expression in malignancy and potential alteration of aromatase promoter use with disease progression.
- A common biallelic polymorphism in the 5'-untranslated region of the CYP19-aromatase gene was associated with significant differences in bone mass and the risk of vertebral fractures in postmenopausal women.
- differences in estrogen levels due to polymorphism at the aromatase CYP19 gene may predispose men to increased age-related bone loss and fracture risk.
- Two stable isomers of ARO were prepared and their expression studied in Escherichia coli.
- CYP19 gene polymorphism increases the risk of breast cancer in premenopausal japanese women.
- Results demonstrate that coumarins or their derivatives can be potent inhibitors of aromatase and may be useful in suppressing aromatase and estrogen receptor-positive breast tumors.
- Expression of aromatase may play a role in the growth of glioblastomas.
- Inhibited by benzoxazolinone imidazoles and derivatives; enzyme isolated from placenta and testis.
- brain P-450arom-ir and the relationship of its regulation with plasma sex steroid levels, estrogen and androgen receptors in the human hypothalamus and basal forebrain are region-specific.
- a common polymorphism of the aromatase gene, in linkage disequilibrium with a functionally significant CYP19 polymorphism, is associated with bone structure and bone turnover, either by local effects or by effects on circulating bioactive estrogen.
- No statistically significant association was found for the CYP19 polymorphism in endometriosis
- concerted interaction of strong placenta-specific enhancers and silencers mediate labyrinthine and syncytiotrophoblast-specific CYP19(aromatase) gene expression
- mutations of the P450arom gene or its promoter are not the cause of polycystic ovary syndrome
- ARO expression was studied in ovarian epithelial cancers.
- Increased aromatase expression is associated with endometrioid endometrial cancer
- common variations of CYP19-aromatase are associated with differences in bone mineral density that seem to be important from an individual as well as from a population perspective
- aromatase haplotype was associated with functional ovarian hyperandrogenism (P < 0.05), independently of insulin sensitivity
- Aromatase enzyme activity in LNCaP and PC3 cells was increased by both 10nM dexamethasone, 1-100 nM calcitriol and 100 n progesterone. T
- Potential role for aromatase inhibition and the stress-response signal ceramide during the therapeutic actions of 15-dPGJ(2) and fenretinide in breast cancer treatment.
- The ability of 2-methoxyoestrone-3-O-sulphamate to block cytokine stimulated aromatase activity suggests that, in addition to its other anti-cancer properties, this compound may also act to inhibit cytokine-stimulated aromatase activity in breast tumours
- A detailed mechanism for the transcriptional regulation of aromatase expression in breast cancer tissue is reviewed.
- The aromatase gene is constitutively expressed both in somatic and germ cells of the testis.
- Aromatase enzyme activity and mRNA levels are readily detectable in endometriosis and uterine leiomyomata.
- Estradiol analogs were much weaker inhibitors than the corresponding estrone compounds in each series, indicating that the 17-carbonyl group plays a critical role in the formation of a thermodynamically stable enzyme-inhibitor complex.
- in Caucasian subjects neither the T/C CYP17 gene polymorphism nor the tetranucleotide repeat (TTTA) polymorphism of the CYP19 gene contributes to the genetic susceptibility to CAD
- To gain insight into the catalytic function of aromatase as well as the mechanism of the hitherto uncertain third oxygenation step, these studies focused on the aromatase-catalyzed 19-oxygenation of 3-deoxyandrogens
- immunohistochemical and in situ hybridization study of CYP19 expression in human arteries from normal and neoplasic uterus
- early in gestation when the placenta is relatively hypoxic, increased USF1/2 may block trophoblast differentiation and CYP19 gene expression
- first study on phytoestrogen-gene associations in men concludes that enterolactone and equol are positively associated with plasma androgen concentrations, and interactions with aromatase(CYP19) gene may be involved
- Recombinant adenoviruses have been used in primary cultures of human placental cells to characterize regulatory regions of the hCYP19 gene and to analyze the function of transcription factors on hCYP19 expression and on trophoblast differentiation.
- enhanced transcription of promotors L3, PII, and I.7 in addition to promotor I.4 explains the upregulation of aromatase mRNA levels in breast cancer tissue
- sodium butyrate regulated aromatase mRNA or activity only via promoters I.3/II but not promoters I.1 or I.4 in breast, ovarian, placental, and hepatic cel
- p450 aromatase may have a role in male infertility associated with chronic inflammation in the testis
- four regulatory regions of promoters pII, I.3 and I.4 are relevant to CYP19 expression in human osteoblasts; vitamin D and dexamethasone modulate transcription through these regions
- This study describes the Aro1 polymorphism which lies within a regulatory region and which may be a functional polymorphism, partially responsible for the bone phenotype it is associated with.
- upregulation of aromatase mRNA and enhanced transcription from promoter PII of florid-type gynecomastia as compared to fibrous-type gynecomastia; COX-2 is suggested to upregulate aromatase expression by enhancing the transcription via promoter Pll
- Aromatase trajectories were investigated following the essential dynamics protocol that allowed the detection of some correlated motions among some protein domains.
- significant positive association with breast cancer development in Brazilians
- Modulators of the cyp19 gene in the cortex and the widespread expression of the protein in specific neuronal and glial subpopulations suggest that local estrogen formation may play an important role in human cortical function.
- Corticotrophin-releasing hormone (CRH) increased whereas alpha-helical CRH decreased the mRNA levels of STS, CYP19A1, and HSD17B1, the key enzymes for estrogen synthesis.
- Review. Benign prostate stroma expresses aromatase. In malignant epithelium, altered promoter use occurs. Although the presence of aromatase & its aberrant expression in prostate cancer is significant, its role in carcinogenesis is unclear.
- Review. The control of aromatase expression via alternative promoters and cyclooxygenase-produced prostaglandins in normal and malignant breast tissue is examined.
- Review. By converting androgens to estrogens, aromatase plays a role in breast and endometrial cancer.
- Review. Aromatase enzyme controls estrogen biosynthesis & thus may exert neuroprotective effects. SNPs in the CYP19 gene are increase the susceptibility for Alzheimer's disease.
- Increased levels of CYP19 mRNA expression is associated with distant metastasis and local recurrence of breast cancer
- Aromatase mRNA level was significantly higher in soft tissue metastases than in primary tumors.
- We found, by reverse transcription--real time--polymerase chain reaction, that the expression of aromatase (CYP19) in ovarian, peritoneal endometriosis, and deep endometriotic nodules is significantly different.
- Aromatase mRNA was higher in epithelial than in stromal cells in eutopic and ectopic endometrium in endometriosis. 17betaHSD2 in epithelial cells was increased during secretory phases compared with late proliferative phase.
- In men, 17beta-estradiol upregulates this enzyme.
- Substrates can regulate the formation of alternative reaction intermediates by modulating the structure on both the heme distal and proximal sites in P450arom.
- Immunohistochemical analysis detected aromatase expression in the endometriotic tissue of 61% of patients, whereas the rest of the tissues, as well as those from disease-free women, were negative.
- upregulation of aromatase combined with downregulation of ERalpha provides a basis for selective action of estradiol produced locally by autocrine or paracrine mechanisms
- The presence of aromatase expression was significantly higher in endometrial polyps than in disease-free endometria.
- more aggressive clinically and frequently receptor-negative type II of endometrial cancer is associated with excess of CYP19 A6A6 genotype
- CYP19 could be one of the genetic factors influencing adult height in Caucasians.
- This study sheds new light on the role of acidic residues present in the active site cavity of human aromatase, which exhibit changes in properties following substrate binding.
- Results describe the feedback regulation of SREBP and aromatase in A beta(25-35)-supplemented human neuroblastoma cells.
- Although granulosa cells in arrested follicles in PCOS fail to express significant amounts of aromatase, there is an overexpression of 5alpha-reductase activity and premature expression of cholesterol side-chain cleavage cytochrome P450.
- 18 single nucleotide polymorphisms spanning the 5'-untranslated region and the entire coding region of CYP19 in 227 patients with AD and 131 control spouses, was examined.
- results suggested that CYP19A1 genetic polymorphisms may be associated with the risk of obesity among Chinese women, especially among premenopausal women
- Data demonstrate that beta-catenin is essential for FSH/cAMP-regulated aromatase gene expression in the ovary.
- The results indicate that aromatase, 17beta-HSD type 7 and 17beta-HSD type 12, but not 17beta-HSD type 1, are commonly expressed in human breast cancer.
- A study evaluating testosterone and estradiol (E2) levels among women in relation to 5 single nucleotide polymorphisms (SNPs) of the aromatase (CYP 19) gene in women of 4 ethnic/racial groups is presented.
- These findings suggest a possible role for CYP19 polymorphisms in estrogen levels and in vasomotor symptoms during the menopausal transition
- Data demonstrate that cyclooxygenase-2 directly regulates gene expression of specific aromatase promoter regions and regulates aromatase enzyme activity.
- In germ cells (GCs), i.e. gonocytes and spermatogonia, aromatase and ERbeta were immunoexpressed strongly whereas no expression of ERalpha, AR, or cP450scc was detected.
- These results suggest that intratumoral 5 alpha-dihydrotestosterone concentration is mainly determined by 5alphaRed1 and aromatase in breast carcinoma tissues.
- A common haplotype of aromatase associated with gene expression is also associated with the risk of osteoporotic vertebral fractures in postmenopausal women.
- CYP19A1 polymorphisms may have roles in breast cancer survival
- Selective spatial upregulation of intratumoral stromal aromatase is associated with breast cancer patients
- Our finding suggests that genetic variations in the CYP19A1 gene are significantly associated with BMD at different skeletal sites in adult men, but not in women.
- Our study suggested that local estrogen production by aromatase plays important roles in the growth and invasiveness of breast cancer.
- Genetic variation in CYP19A1 produces measurable differences in estrogen levels among postmenopausal women.
- atrazine binds to and activates steroidogenic factor 1 to induce ArPII
- Molecular alterations such as the presence of aromatase in endometriotic tissues could be involved in the development or maintenance of endometriosis.
- No statistically significant association exists between the CYP17 and CYP19 trinucleotide deletion polymorphisms and the risk of idiopathic recurrent miscarriages among women from South India
- no evidence that haplotype of CYP19 was associated with percentage mammographic density in women
- This paper reviews the influence of aromatase activity and aromatase gene variants on skeletal homeostasis and the prevention and management of osteoporosis.
- Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency are reported.
- No endometrial cancer specimen showed expression of aromatase, therefore it might not have an important role in endometrial cancer.
- The cP450arom and GPR30 expression in subcapsular zona glomerulus, colocalizing with a high-cell proliferation index suggests a local GPR30-dependent estrogen action in proliferation and migration of progenitor adrenal cells
- Activity of this enzyme in endometrial cancer obtained by tritium-labeld steroids.
- results of our study have shown that the CYP19 TCT Del/Del genotype might be a susceptibility marker for prostate cancer; men with the Ins-A6 haplotype had a lower risk of developing prostate cancer
- Our data show that polymorphisms in the CYP19A1 gene may contribute to endometrial carcinogenesis.
- Mullerian-inhibiting substance inhibits FSH augmentation of CYP19 enzyme activity and CYP19 gene expression in granulosa lutein cells.
- polymorphism of genes involving estrogen-metabolizing pathway, estrogen- biosynthesizing pathway and estrogen receptor pathway may play an important role in the etiology of BRCA1/2 negative breast cancer with hereditary predisposing factors.
- These results suggest that the suppression of aromatase activity and its transcription level by MEHP exposure to NCI-H295R cells was regulated through the rapid and transient expression of Nur77 gene.
- Small rearrangements may create cryptic promoters that direct inappropriate transcription of CYP19 or other critical genes.
- Mutations R457H and V492E located in the FAD domain of NADPH P450 oxidoreductase (POR) that disrupt electron transfer caused a complete loss of CYP19A1 activity.
- Data report association of a 3-bp deletion polymorphism of the (TTTA)7 allele with decreased peak bone mass in males.
- This study demonstrates a strong positive relationship between COX-2 and aromatase mRNA expression, and lends further support to the hypothesis that COX-2 is an upregulator of aromatase in breast tissue.
- Significantly higher stromal aromatase expression was associated with invasive breast cancer
- An epigenetic disorder may cause aberrant expression of aromatase gene in endometriotic stromal cells.
- Aberrant mRNA expression of aromatase, cytokines, and adhesion factors in endometrium and peritoneum suggests that both tissues are involved in the pathogenesis of endometriosis.
- DDT/DDE inhibited placental aromatase activity to decrease estradiol secretion and may influence pregnancy outcome.
- The results suggest that the CYP19 polymorphism may not be linked with appearance and development of endometrial cancer
- CYP19 genetic polymorphisms are not associated with advanced-stage endometriosis in Korean women.
- POLYMORPHISM OF CYP1B1 AND CYP19 WERE ASSOCIATED WITH RISK OF PROSTATE CANCER
- Resveratrol inhibits aromatase activty and reduces mRNA abundance in placental cells.
- Three CYP19A1 polymorphisms (rs1065779, rs752760, rs1870050) are related to risk of endometrial cancer, effects modified by tea consumption.
- The CYP19A1 gene may be involved in the genetic regulation of BP in women. This effect is dependent on BMI and independent of menopause status, suggesting that this action is mainly driven by aromatase activity in fat tissue.
- Use of an aromatase inhibitor for ovulation induction does not eliminate the risk for higher order multiple pregnancy.
- A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk.
- Overexpression of endometrial aromatase may underlie pathogenesis of endometrial polyps at least in a subset of cases.
- Loss of aromatase is associated with breast cancer.
- Aromatase expression in eutopic endometrium from endometriosis patients was significantly increased.
- Single nucleotide polymorphisms of the aromatase gene is associated with a lower percentage of HER2-positive breast tumors.
- PGE(2) via EP(2) and EP(4) activates the cAMP-->PKA-->CREB pathway leading to enhanced CYP19 transcription and increased aromatase activity through BRCA1 and p300
- Adrenal cortical carcinomas are character- ized by an imbalance between estrogen receptor alpha and estrogen receptor beta levels and increased aromatase expression.
- Aromatase is expressed in SGBS adipocyte cells and its expression and activity are strongly stimulated by forskolin (FSK) and phorbol 12-myristate-13-acetate (PMA) treatment
- C/EBPbeta, which binds to multiple cis-regulatory elements in promoter I.3/II, is a key factor in the transcriptional complex controlling aromatase expression in uterine leiomyoma cells.
- No single nucleotide polymorphisms and the (TTTA)(n) repeat polymorphisms of CYP19A1 are associated with breast cancer
- The methylation status of 6 CpG dinucleotides within a 571-bp fragment of promoter I.3/II containing a cAMP response element in cAMP-responsive (n=1) or nonresponsive (n=3) primary skin fibroblasts, is described.
- Single nucleotide polymorphism is a predictive tool for breast cancer patients on antiaromatase therapy which deserves prospective evaluation.
- rs700518 and rs10046, as well as a haplotype constructed with rs1870049 and rs10046, can be used as genetic markers for gender-specific essential hypertension
- Subjects carrying both the aromatase (5 -UTR) GG and the IL-10 (-1082) GG genotypes had a six times lower risk of developing AD than subjects without these risk genotypes (OR = 0.17, 95% CI = 0.04-0.77, P = 0.02).
- CYP19 polymorphisms might contribute to the incidence of gynecomastia, but further studies in larger groups are needed to confirm these results
- The insertion/deletion variant in CYP19A1 (cytochrome P450 family 19 subfamily A polypeptide 1)appears to be related to risk of endometrial cancer; risk associated with variants in this gene may vary according to Body mass idnex
- The mRNA and protein levels for P450 aromatase were undetectable in all analyzed endometria.
- These findings suggest that PR plays an important antiinflammatory role in breast cancer cells via ligand-dependent and ligand-independent mechanisms.
- In North Indian population, ERalpha and CYP19 genes may be playing a role in the risk of prostate cancer.
- CYP19 polymorphism is associated with ovarian cancer and endometrial cancer
- Data indicate that SHBG and CYP19 genes may have a synergistic role in the developmental programming of polycystic ovary syndrome, by affecting androgen bioavailability and aromatization respectively.
- the aromatase gene is expressed in bone tissue in high amounts, similar to those found in adipose tissue; transcript levels are lower in tissue samples and osteoblast cultures from patients with osteoarthritis than in those from patients with hip fractur
- Exposure of endometrial cells to androstenedione may enhance CYP19 gene expression through its aromatization to estrogens.
- The tumoral tissues exhibited positive staining for anti-aromatase antibody.
- present findings suggest that CYP17A1, CYP19, and androgen receptor polymorphisms are unlikely to be associated with an increased risk of uterine leiomyomas in Brazilian women
- The role of the aromatase gene in the progression of breast cancer was studied.
- The CYP19 TTTA repeat polymorphism is associated with survival in premenopausal women, but not in postmenopausal women, with hormone receptor-positive breast cancers
- Single nucleotide polymorphisms in blocks 1 and 2 of the CYP19A1 gene are related to plasma levels of estrogen among postmenopausal Chinese women and may therefore play an important role in the etiology of hormone-related cancers.
- Single-nucleotide polymorphisms in the CYP19A1 is associated with ovarian cancer.
- phosphorylation of S118 may decrease aromatase activity, presenting a mechanism whereby kinase signaling may modulate estrogen production and hormone balance.
- both SF1 and LRH1 can transcriptionally cooperate with the AP-1 family members c-JUN and c-FOS, known to be associated with enhanced proliferation of endometrial carcinoma cells, to further enhance activation of the STAR, HSD3B2, and CYP19A1 PII promoter
- The risk of breast cancer with proliferative fibrocystic conditions was increased among women homozygous for the minor allele of rs1004982(C), rs28566535(C), rs936306(T), and rs4775936(C) relative to those homozygous for the major allele.
- No association between CYP19 polymorphisms and risk for hepatocellular carcinoma.
- There was a down-regulation of ERalpha and aromatase in the stroma of obese prostate cancer patients compared to patients with normal weight.
- Common variants in CYP19A1 (the A alleles of rs749292 and rs727479) influences susceptibility to endometrial cancer, particularly among older and obese women.
- crystal structure of human placental aromatase, the only natural mammalian, full-length P450 and P450 in hormone biosynthetic pathways to be crystallized so far
- Aromatase expression by endometrial epithelial and stromal cells is an important part in pahtogenesis of endometriosis.